FDA
-
-
-
-
-
-
-
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Kyverna outlines phase 3 trial design for myasthenia gravis therapy
-
-
-
-
-
-
-
ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX)
-
-
-
-
-
-
-
Kyverna Therapeutics Inc (KYTX) PT Lowered to $7 at H.C. Wainwright
-
-
-
-
-
-
-
Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
-
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

